Communicable Disease Market: A BCC Research Overview
Publish Date: May 2019 | Category: Healthcare, Pharmaceuticals & Medical Devices | Publisher: BCC Research | Status: Publish
The global market for communicable disease should grow from $57.7 billion in 2019 to $69.4 billion by 2024 at a compound annual growth rate (CAGR) of 3.8% for the period of 2019-2024.
The scope of this report is broad and covers therapeutics used in treatment of communicable diseases. The report highlights the current and future market potential of communicable diseases therapeutics and provides a detailed analysis of the competitive environment, regulations, epidemiology of communicable diseases, merger and acquisition, drivers, restraints, and pipeline drugs in the market. The report also covers market projections through 2024.
The report details market shares of communicable diseases based on different disease indication. Based on disease indication the market is segmented into HIV, Hepatitis B&C, Herpes Simplex Virus, Influenza, Malaria, Tuberculosis, and Others.
The market is segmented by geography into the following regions: North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. The report presents detailed analyses of major countries such as the U.S., Canada, Mexico, Germany, the U.K. France, Spain, Italy, Japan, China and India. For market estimates, data is provided for 2018 as the base year, with forecasts for 2019 through 2024. Estimated values are based on product manufacturers’ total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.
- 23 data tables and 24 additional tables - Detailed overview of the global market for communicable diseases within the healthcare industry - Analyses of the global market trends, with data from 2018, estimates for 2019, and projections of compound annual growth rates (CAGRs) through 2024 - Regional analysis of the communicable disease market, covering North America, Europe, Asia-Pacific, South America and Middle East & Africa - A look at the government regulations pertaining to drug developments for communicable diseases and pipeline analysis covering ongoing clinical trials and promising forthcoming therapies in late stage - Discussion of competitive landscape, mergers and acquisitions of companies to enhance their product portfolio, and future commercial marketplace - Comprehensive company profiles of major market players, including Abbott Laboratories, AbbVie Inc., GlaxoSmithKline Plc, Novartis AG and Pfizer Inc.
The global market for communicable disease was valued at REDACTED in 2018. The market is expected to grow at a compound annual growth rate (CAGR) of REDACTED to reach approximately REDACTED by 2024. The market is expected to grow during the forecast period owing to rising prevalence of sexually transmitted diseases, growing awareness regarding communicable diseases, development of novel therapies, and growing public and private partnership for research of new therapies.
The global communicable disease market is segmented based on disease indication and region.
North America is estimated to have the highest market share and the Asia-Pacific region is anticipated to have the highest growth rate during the forecast period. The increase in health care expenditure in the Asia-Pacific market, growing research and development activities, and increase in prevalence of STDs, HIV, and infectious diseases coupled with growing government initiative in creating awareness regarding communicable disease are the major factors augmenting the growth of communicable disease market in the Asia-Pacific region.
Table of Contents
Chapter 1 Introduction Study Goals and Objectives Reasons for Doing This Study Scope of Report Information Sources Methodology Geographic Breakdown Analyst's Credentials BCC Custom Research Related BCC Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background Disease Overview HIV HIV Timeline and Milestones HIV Life Cycle: Treatment and Mechanism of Action HIV Prophylaxis Epidemiology Chlamydia Epidemiology Genital Herpes Epidemiology Gonorrhea Epidemiology Hepatitis A, B and C Epidemiology HPV Syphilis Epidemiology Malaria Incidence and Geographical Distribution Tuberculosis Incidence and Geographical Distribution Influenza Incidence and Mortality Trichomoniasis Scabies Bacterial Vaginosis Candidiasis Chancroid (Venereal Ulcers) Pediculosis Pubis
Chapter 4 Market Dynamics Market Drivers Regional Awareness Program for Communicable Diseases Development of Novel Therapies Public Private Partnership Global Program to Counter HIV Increasing Prevalence of Communicable Diseases Market Restraints Social Stigma Associated with STD High Cost of Treatment Underestimating the Risk of Contracting the Disease Lack of Prenatal Screenings for STD
Chapter 5 Market Breakdown by Disease Type Global Market for Communicable Disease, by Disease Indication HIV Market Size and Forecast Market Analysis Hepatitis B&C Market Size and Forecast Market Analysis Herpes Simplex Virus Market Size and Forecast Market Analysis Influenza Market Size and Forecast Market Analysis Malaria Market Size and Forecast Market Analysis Tuberculosis Market Size and Forecast Market Analysis Others Market Size and Forecast Market Analysis
Chapter 6 Market Breakdown by Region Global Market for Communicable Disease, by Region North America U.S. Canada Mexico Europe Germany France U.K. Spain Italy Rest of Europe Asia-Pacific Japan China India Rest of Asia-Pacific South America Middle East & Africa
Chapter 7 Pipeline Analysis Overview Hepatitis B and Hepatitis C Herpes Simplex Virus HIV/AIDS Influenza A and Influenza B Respiratory Syncytial Virus Malaria Tuberculosis MERS Hemorrhagic Fevers Dengue Ebola Lassa fever Marburg Yellow Fever Zika
Chapter 8 Regulation and Reimbursement Regulations U.S. Europe Japan China Pricing and Reimbursement U.S. Europe Japan
Chapter 9 Competitive Landscape Sexually Transmitted Disease Therapeutics: Global Competitor Analysis Influenza Therapeutics: Global Competitor Analysis
Chapter 10 Company Profiles ABBOTT LABORATORIES ABBVIE INC. ASTRAZENECA/MEDIMMUNE AUROBINDO PHARMA LTD. BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. BRISTOL-MYERS SQUIBB CO. CIPLA INC. DAIICHI SANKYO GILEAD SCIENCES, INC. GLAXOSMITHKLINE PLC JANSSEN PHARMACEUTICALS, INC. MERCK & CO., INC. MITSUBISHI TANABE PHARMA CORP. MYLAN LABORATORIES NOVARTIS AG PFIZER INC. HOFFMANN-LA ROCHE INC. SANOFI, SANOFI PASTEUR SEQIRUS, A CSL COMPANY VIIV HEALTHCARE